---

---

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K
 
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

Date of Report: November 7, 2016
Commission File Number: 001-36891

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☑ Form 40-F ⃞

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ⃞

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ⃞

---

---

EXHIBIT INDEX

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

3

Exhibit 99.1

Cellectis Announces Two Oral Presentations and One Poster at the 2016 ASH Annual Meeting

NEW YORK--(BUSINESS WIRE)--November 7, 2016--Regulatory News:

Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART), today announced that abstracts regarding the Company's allogeneic, off-the-shelf, CAR T programs have been accepted for presentation at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition. The meeting will be held December 3-6, 2016 in San Diego.

Oral presentations:

• 765 Allogeneic Tcrα/β Deficient CAR T-Cells Targeting CD123 Prolong Overall Survival of AML Patient-Derived Xenografts

  https://ash.confex.com/ash/2016/webprogram/Paper97033.html

Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation
Program: Oral and Poster Abstracts
Type: Oral
Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Emerging Immune-Based Therapies for AML
Monday, December 5, 2016: 11:00 AM
San Diego Ballroom AB (Marriott Marquis San Diego Marina)

Monica L. Guzman, PhD¹, Mayumi Sugita, MD^1*, Hongliang Zong, MD, PhD^1*, Nathan Ewing-Crystal^1*, Vicenta Trujillo-Alonso^1*, Nuria Mencia-Trinchant, PhD^1*, Linda Lam^1*, Nicole M. Cruz, MD¹, Roman Galetto, PhD^2*, Agnès Gouble, PhD^2*, Duane C Hassane, PhD¹, Julianne Smith, PhD² and Gail J. Roboz^3
1Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY
²Cellectis SA, Paris, France
³Weill Cornell Medical College, New York, NY

• 381 Preclinical Evaluation of Allogeneic Anti-Bcma Chimeric Antigen Receptor T Cells with Safety Switch Domains and Lymphodepletion Resistance for the Treatment of Multiple Myeloma

  https://ash.confex.com/ash/2016/webprogram/Paper90155.html

Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy
Program: Oral and Poster Abstracts
Type: Oral
Session: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Novel Immune Approaches for Myeloma Therapy
Sunday, December 4, 2016: 12:30 PM
Grand Hall B (Manchester Grand Hyatt San Diego)

Bijan Boldajipour, PhD^1*, Roman Galetto, PhD^2*, Cesar Sommer, PhD^1*, Thomas Pertel, PhD^1*, Julien Valton, PhD^3*, Yoon Park, PhD^1*, Annabelle Gariboldi^2*, Amy Chen^1*, Tao Geng^1*, Hong H Dong^1*, Gregory R Boucher^1*, Thomas J Van Blarcom, PhD^1*, Javier Chaparro-Riggers, PhD^1*, Arvind Rajpal, PhD^1*, Julianne Smith, PhD³, Tracy Kuo, PhD^1* and Barbra Sasu, PhD^1
1Pfizer Inc., South San Francisco, CA
²Cellectis SA, Paris, France
³Cellectis Inc., New York, NY

Poster presentation:

• 4039 Pre-Clinical Studies of Anti-CD123 CAR-T Cells for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

  https://ash.confex.com/ash/2016/webprogram/Paper95092.html

Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation
Program: Oral and Poster Abstracts
Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster III
Monday, December 5, 2016, 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)

Tianyu Cai, PhD^1*, Roman Galetto, PhD^2*, Agnès Gouble, PhD^2*, Julianne Smith, PhD², Antonio Cavazos, MS^1*, Sergej Konoplev, MD, PhD³, Andrew A. Lane, MD, PhD⁴, Monica L. Guzman, PhD⁵, Hagop M. Kantarjian, MD¹, Naveen Pemmaraju, MD¹ and Marina Konopleva, MD, PhD^1
1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
²Cellectis SA, Paris, France
³Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
⁴Dana-Farber Cancer Institute, Boston, MA
⁵Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY

About Cellectis

Cellectis is a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART). The company’s mission is to develop a new generation of cancer therapies based on engineered T-cells. Cellectis capitalizes on its 16 years of expertise in genome engineering - based on its flagship TALEN® products and meganucleases and pioneering electroporation PulseAgile technology - to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells. Using its life-science-focused, pioneering genome-engineering technologies, Cellectis’ goal is to create innovative products in multiple fields and with various target markets.

In June 2014, Cellectis and Pfizer began collaborating on a joint clinical development program for CAR-T therapies, in the field of oncology, directed at numerous targets selected by Pfizer.

Cellectis is listed on the Nasdaq market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com

Talking about gene editing? We do it. TALEN® is a registered trademark owned by the Cellectis Group.

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company’s objectives based on the current expectations and assumptions of the Company’s management only and involve risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.

CONTACT:
Media:
Jennifer Moore, 917-580-1088
VP of Communications
media@cellectis.com
or
Caitlin Kasunich, 212-896-1241
KCSA Strategic Communications
ckasunich@kcsa.com
or
IR:
Simon Harnest, 646-385-9008
VP of Corporate Strategy and Finance
simon.harnest@cellectis.com